Lineage OPC1 Investor & Analyst Day 2021

February 22, 2021

View Archived Webcast here - https://showroom.troutaccess.com/app?iframe=1#/webcast/GXFE3E

 

Please join us for a call with Lineage management and therapeutic area expert Edward Wirth, M.D., Ph.D., for an update on Lineage’s OPC1 program. OPC1 is an oligodendrocyte progenitor cell (OPC) transplant therapy designed to provide clinically meaningful improvements in motor recovery in individuals with acute spinal cord injuries (SCI). The OPC1 program has been partially funded by a $14.3 million grant from the California Institute for Regenerative Medicine and has received Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug designation from the U.S. Food and Drug Administration. In December 2020, Lineage announced significant enhancements to OPC1 production, including to process, purity, potency, and scale. In February 2021, Lineage announced that it has entered into an exclusive agreement with Neurgain Technologies, Inc. to evaluate a novel delivery system for OPC1, which could support later-stage clinical trials of OPC1 in cervical injury patients.

 

Moderator: Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research - Equity Research, Maxim Group LLC

Jason McCarthy, Ph.D. is a Senior Managing Director covering the biotechnology industry at Maxim Group. Dr. McCarthy joined Maxim Group in July 2014. Prior to joining Maxim he received his doctoral degree in Biomedical Sciences at the Albert Einstein College of Medicine. Dr. McCarthy also holds Master’s degree in both Biomedical Research (Albert Einstein College of Medicine) and Molecular Biology (Adelphi University), as well as a B.S. in Biochemistry from Stony Brook University.

 

Therapeutic Expert: Edward Wirth, III, M.D., Ph.D.

Dr. Wirth currently serves as Chief Medical Officer at Aspen Neuroscience. Dr. Wirth’s specialties include clinical trials, translational research, stem cells, cell based therapies, magnetic resonance imaging, spinal cord injury and neurological disorders.

Dr. Edward Wirth completed the M.D./Ph.D. program at the University of Florida (UF) in 1994. He elected to remain at UF to conduct postdoctoral research, and subsequently joined the faculty in 1996. From 1997 to 2002, Dr. Wirth led the UF team that performed the first human embryonic spinal cord transplant in the United States. This pilot study demonstrated the feasibility and safety of implanting embryonic spinal cord cells into patients with post-traumatic syringomyelia (a complication of spinal cord injury). From 2002 to 2004, Dr. Wirth held academic appointments at Rush Presbyterian St. Luke’s Medical Center and at the University of Chicago. From 2004-2011, he served as Medical Director for Regenerative Medicine at Geron Corporation, where he led the world’s first clinical trial of a human embryonic stem cell (hESC)-derived product. In 2013 he joined several former Geron colleagues at Asterias Biotherapeutics, which had acquired the stem cell assets of Geron. He served as Asterias' Chief Translational Officer from 2013-2015 and Chief Medical Officer from 2015-2019. At Asterias he led the expansion and completion of the former Geron clinical trial, which demonstrated the initial clinical safety and activity of OPC1 in patients with subacute spinal cord injuries. He next served at Chief Medical Officer at Lineage Cell Therapeutics, which acquired Asterias in March 2019. Dr. Wirth currently serves as Chief Medical Officer at Aspen Neuroscience.
Dr. Wirth’s specialties include clinical trials, translational research, stem cells, cell based therapies, magnetic resonance imaging, spinal cord injury and neurological disorders. 

 

Lineage Cell Therapeutics: From Paralysis to Pitching – Improving Mobility After a Severe Spinal Cord Injury

Webinar hosted on October 22, 2020, discussing Lineage’s OPC1 program and the spinal cord injury disease landscape, treatment approaches, and the commercial opportunity of restoring mobility to individuals who have been paralyzed by a cervical spinal cord injury.

RSVP for Event / Log Back in Presenter Access

Additional menu options can be found in the menu bar on the left or at the top.

Lineage Cell Therapeutics Inc. [LCTX] $369 MM MCap
Cell ther­a­py com­pany with 3 cl­ni­cal pro­grams 1) OpRe­gen, an RPE tran­s­plant ther­a­py in Ph1/2a de­vel­op­ment for the treat­ment of dry-AMD. 2) OPC1, an oli­go­den­dro­cyte pro­gen­i­tor cell ther­a­py for acute spi­nal cord in­juries with Or­phan and RMAT desig­na­tions. 3) VAC2, an al­lo­gene­ic can­cer im­munother­a­py of anti­gen-pre­sent­ing den­drit­ic cells cur­rent­ly in a Ph 1 for NS­CLC con­duct­ed by CRUK. [more in­for­ma­tion]

Event Contact

Gitanjali Jain Ogawa
Solebury Trout